Therefore, VEGFR2 inhibition via ramucirumab treatment may provide additional clinical benefit when added to other cytotoxic agents, including those used during pediatric cancer treatment such as vincristine, irinotecan, and temozolomide [5] or targeted agents with unique mechanisms-of-action currently being explored in the pediatric population. This evidence concerns the gene KDR and cancer.